Vivos Therapeutics Announces Positive Clinical Trial Results for Pediatric Obstructive Sleep Apnea Treatment Using Patented DNA Appliance

Vivos Therapeutics (VVOS) announced positive multicenter clinical trial results for its FDA-cleared Daytime-Nighttime Appliance (DNA), published in the European Journal of Pediatrics, demonstrating significant efficacy in treating pediatric obstructive sleep apnea (OSA). The study reported 79% of child participants showed improvement and 17% achieved symptom resolution, positioning the non-invasive device as a compelling alternative to traditional adenotonsillectomy, which has a high relapse rate. This validation strengthens Vivos' market position in addressing the substantial unmet need in pediatric OSA, despite the study's limited sample size and general forward-looking statement risks.

Analysis

Vivos Therapeutics (VVOS) has significantly bolstered the clinical case for its pediatric Daytime-Nighttime Appliance (DNA) with the publication of positive multicenter trial results in the European Journal of Pediatrics. The study demonstrated notable efficacy, with 79% of the 47 participants showing improvement in obstructive sleep apnea (OSA) and 17% experiencing complete resolution, reinforcing the FDA 510(k) clearance received in September 2024. This positions the non-invasive DNA device as a compelling alternative to adenotonsillectomy, the current standard of care, which the article notes has a high relapse rate of 68% within three years. The news aligns with Vivos' strategy to increase patient access through acquisitions, such as the Sleep Center of Nevada, targeting a large and mostly undiagnosed market of an estimated 10 million children in the U.S. However, the study's limited sample size of 47 subjects presents a key risk to the broad applicability of these findings. Furthermore, institutional holdings data from previous quarters reveals a mixed sentiment, with several funds eliminating their positions in Q4 2024, juxtaposed against smaller new positions from firms like Vanguard and Royal Bank of Canada in Q1 2025, suggesting this new data may be a critical catalyst for shifting investor conviction.

Key Decisions for Investors

• The positive, peer-reviewed clinical data significantly de-risks the DNA device's efficacy profile, supporting a potential re-rating of the stock as it validates a key growth driver in the pediatric OSA market.
• Investors should monitor the company's execution on its commercial strategy, particularly the integration of the Sleep Center of Nevada acquisition and any resulting impact on revenue, as this will be the primary test of converting clinical success into financial results.
• The small trial size of 47 participants remains a material concern, and future catalysts to watch for include announcements of larger-scale studies or real-world evidence that could confirm these findings and drive broader clinical adoption.
• Given the mixed institutional sentiment prior to this news, a key indicator will be institutional ownership changes in the upcoming 13F filing period, which will reveal if this data has successfully attracted new long-term investors or reversed prior bearish stances.